31 related articles for article (PubMed ID: 24939677)
1. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study.
Hansen RL; Jørgensen TS; Egeberg A; Rosenø NAL; Skougaard M; Stisen ZR; Dreyer L; Kristensen LE
Rheumatology (Oxford); 2024 May; 63(6):1593-1598. PubMed ID: 37647648
[TBL] [Abstract][Full Text] [Related]
2. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
Linde L; Ørnbjerg LM; Georgiadis S; H Rasmussen S; Lindström U; Askling J; Michelsen B; Di Giuseppe D; Wallman JK; Gudbjornsson B; Love TJ; Nordström DC; Yli-Kerttula T; Nekvindová L; Vencovský J; Iannone F; Cauli A; Loft AG; Glintborg B; Laas K; Rotar Z; Tomšič M; Macfarlane GJ; Möller B; van de Sande M; Codreanu C; Nissen MJ; Birlik M; Erten S; Santos MJ; Vieira-Sousa E; Hetland ML; Østergaard M
Rheumatology (Oxford); 2024 Mar; 63(3):751-764. PubMed ID: 37314967
[TBL] [Abstract][Full Text] [Related]
3. Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration.
Linde L; Ørnbjerg LM; Rasmussen SH; Love TJ; Loft AG; Závada J; Vencovský J; Laas K; Nordstrom D; Sokka-Isler T; Gudbjornsson B; Gröndal G; Iannone F; Ramonda R; Hellamand P; Kristianslund EK; Kvien TK; Rodrigues AM; Santos MJ; Codreanu C; Rotar Z; Tomšič M; Castrejon I; Díaz-Gonzáles F; Di Giuseppe D; Ljung L; Nissen MJ; Ciurea A; Macfarlane GJ; Heddle M; Glintborg B; Østergaard M; Hetland ML
Arthritis Res Ther; 2023 Oct; 25(1):205. PubMed ID: 37858143
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
[TBL] [Abstract][Full Text] [Related]
5. Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis.
Lee SS; Kim TH; Park W; Song YW; Suh CH; Kim SK; Yoo DH
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640586
[TBL] [Abstract][Full Text] [Related]
6. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
Palsson O; Love TJ; Gunnarsdottir AI; Gunnarsson PS; Runarsdottir EE; Krogh NS; Gudbjornsson B
RMD Open; 2019; 5(2):e000984. PubMed ID: 31413869
[TBL] [Abstract][Full Text] [Related]
7. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
8. Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.
Hebeisen M; Scherer A; Micheroli R; Nissen MJ; Tamborrini G; Möller B; Zufferey P; Exer P; Ciurea A
PLoS One; 2019; 14(5):e0216746. PubMed ID: 31145730
[TBL] [Abstract][Full Text] [Related]
9. A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences.
Maniadakis N; Toth E; Schiff M; Wang X; Nassim M; Szegvari B; Mountian I; Curtis JR
Adv Ther; 2018 Sep; 35(9):1333-1355. PubMed ID: 30078176
[TBL] [Abstract][Full Text] [Related]
10. Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry.
Gudbjornsson B; Geirsson AJ; Krogh NS
Psoriasis (Auckl); 2018; 8():13-19. PubMed ID: 29765870
[TBL] [Abstract][Full Text] [Related]
11. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordström D; Aaltonen K; Törmänen MR; Klami Kristianslund E; Kvien TK; Provan SA; Björn Guðbjörnsson B; Dreyer L; Kristensen LE; Jørgensen TS; Jacobsson L; Askling J
RMD Open; 2018; 4(1):e000655. PubMed ID: 29682328
[TBL] [Abstract][Full Text] [Related]
12. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Watson KD; Packham J; Contributors Group BR; Symmons DPM; Hyrich KL
RMD Open; 2018; 4(1):e000596. PubMed ID: 29479475
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.
Coates LC; Kishimoto M; Gottlieb A; Shuler CL; Lin CY; Lee CH; Mease PJ
RMD Open; 2017; 3(2):e000567. PubMed ID: 29299340
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.
Mease PJ; Collier DH; Saunders KC; Li G; Kremer JM; Greenberg JD
RMD Open; 2015; 1(1):e000181. PubMed ID: 26819748
[TBL] [Abstract][Full Text] [Related]
15. Lower Dose Infliximab for Ulcerative Colitis: How Low Can We Go and How Much Can be Saved?
Christophi GP; Ciorba MA
J Clin Gastroenterol; 2015 Aug; 49(7):539-40. PubMed ID: 26057322
[No Abstract] [Full Text] [Related]
16. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
Glintborg B; Gudbjornsson B; Krogh NS; Omerovic E; Manilo N; Holland-Fischer M; Lindegaard HM; Loft AG; Nordin H; Johnsen L; Oeftiger SF; Hansen A; Rasmussen C; Grondal G; Geirsson AJ; Hetland ML
Rheumatology (Oxford); 2014 Nov; 53(11):2100-9. PubMed ID: 24939677
[TBL] [Abstract][Full Text] [Related]
17. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
18. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
19. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
